Phase 1 Study of HSP90 Inhibitor Ganetespib with Pemetrexed and Cisplatin/Carboplatin Chemotherapy for Pleural Mesothelioma

被引：2

作者：

Fennell, D. ^{[1
]}

Danson, S. ^{[2
]}

Forster, M. ^{[3
]}

Talbot, D. ^{[4
]}

Woll, P. ^{[5
]}

Child, J. ^{[6
]}

Ngai, Y. ^{[6
]}

Farrelly, L. ^{[6
]}

Hackshaw, A. ^{[6
]}

Sharkey, A. ^{[1
]}

Busacca, S. ^{[1
]}

Hastings, R. ^{[1
]}

Barnes, D. ^{[7
]}

Nicolson, M. ^{[8
]}

Taylor, P. ^{[9
]}

Ahmed, S. ^{[7
]}

Wheeler, G. ^{[6
]}

机构：

[1] Univ Leicester, Leicester, Leics, England

[2] Univ Sheffield, Sheffield Ecmc, Sheffield, S Yorkshire, England

[3] Univ Coll London Hosp, CRUK Luncer Canc Ctr Excellence, London, England

[4] Univ Oxford, Dept Oncol, Oxford, England

[5] Univ Sheffield, Weston Pk Hosp, Dept Oncol, Sheffield, S Yorkshire, England

[6] UCL, Canc Res UK & UCL Canc Trials Ctr, London, England

[7] Univ Hosp Leicester NHS Trust, Leicester, Leics, England

[8] Aberdeen Royal Infirm, Aberdeen, Scotland

[9] Manchester Univ NHS Fdn Trust, Wythenshawe Hosp, Manchester, Lancs, England

来源：

JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期

关键词：

HSP90; inhibition; Dose-escalation; Pleural mesothelioma;

D O I：

10.1016/j.jtho.2018.08.415

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA12.05

引用

页码：S397 / S397

页数：1

共 50 条

[1] Recent updates on the development of ganetespib as a Hsp90 inhibitor
Choi, Hyun Kyung
Lee, Kyeong
ARCHIVES OF PHARMACAL RESEARCH, 2012, 35 (11) : 1855 - 1859
[2] Recent updates on the development of ganetespib as a Hsp90 inhibitor
Hyun Kyung Choi
Kyeong Lee
Archives of Pharmacal Research, 2012, 35 : 1855 - 1859
[3] Significant response to carboplatin/pemetrexed chemotherapy in malignant pleural mesothelioma
Futtam, L.
Carney, D.
McCaffrey, J.
LUNG CANCER, 2010, 67 : S20 - S20
[4] Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma
Ceresoli, GL
Zucali, PA
Favaretto, AG
Grossi, F
Bidoli, P
Del Conte, G
Ceribelli, A
Bearz, A
Morenghi, E
Cavina, R
Marangolo, M
Parra, HJS
Santoro, A
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (09) : 1443 - 1448
[5] Targeting KRAS mutant NSCLC with the Hsp90 inhibitor ganetespib
Acquaviva, Jaime
Smith, Don
Sang, Jim
Wada, Yumiko
Proia, David A.
CLINICAL CANCER RESEARCH, 2012, 18 (03)
[6] The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells
Gomez-Casal, Roberto
Bhattacharya, Chitralekha
Epperly, Michael W.
Basse, Per H.
Wang, Hong
Wang, Xinhui
Proia, David A.
Greenberger, Joel S.
Socinski, Mark A.
Levina, Vera
CANCERS, 2015, 7 (02) : 876 - 907
[7] Antiangiogenic activity of the HSP90 inhibitor ganetespib in pancreatic cancer models
Ganji, Purnachandra Nagaraju
Diaz, Roberto
El-Rayes, Bassel
FASEB JOURNAL, 2013, 27
[8] A phase II study of pemetrexed and carboplatin as front-line chemotherapy in patients with malignant pleural mesothelioma (MPM)
Zucali, P. A.
Ceresoli, G. L.
Favaretto, A. G.
Cortinovis, D.
Grossi, F.
Marangolo, M.
Del Conte, G.
Ceribelli, A.
Bearz, A.
Parra, H. Soto
Santoro, A.
ANNALS OF ONCOLOGY, 2005, 16 : 28 - 28
[9] Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models
Lin, Shu-Fu
Lin, Jen-Der
Hsueh, Chuen
Chou, Ting-Chao
Yeh, Chun-Nan
Chen, Ming-Huang
Wong, Richard J.
ONCOTARGET, 2017, 8 (25) : 41294 - 41304
[10] A phase II study of pemetrexed and carboplatin as front-line chemotherapy in patients with malignant pleural mesothelioma (MPM)
Parra, HS
Zucali, R
Favaretto, A
Grossi, F
Fusi, A
Marangolo, M
Del Conte, G
Ceribelli, A
Bearz, A
Ceresoli, G
LUNG CANCER, 2005, 49 : S229 - S229

← 1 2 3 4 5 →